and institutions staying out until some significant news develops. MM will do his job to maximize his business. However, the company is moving ahead solidly and step-by-step to be a formidable entity in the oncology arena. Imetelstat has to be brought to the market ASAP for myeloid applications before applications to other cancers are searched actively by the company. Can the company do it alone? I doubt because it doesn't have the marketing ability nor the managing ability for such a global commercial operation. It has to find a partner or get merged with a pharma with wide shoulders. Doing so with an outfit like Amgen or Biogen would have been in the current management's plan, perhaps after reaching Ph III for the MF trial by the company so that a best deal can be reached. Until then, longs need to be patient and, the monkeys have the ground to play their games as dictated by the MM. When things become clear to the MM (secretly), he will lead the share price consistently above $5 to lure institutional players. Then, the monkeys' game will be over for ever!!!
Black, to judge appropriately what and why did the Geron management did what it deed, you have to be in the board! Getting rid of controversial hESC side and concentrating on the future of Imetelstat that looked disasterous last year to us doesn't seem right anymore. Expulsion of Okarma followed by trimming the other staff, including the CFO Cooper and putting Huh as COB, should be kept in mind before we judge the past actions and extrapolate the company's immediate future. To me now, accordingly, company's future doesn't look bad at all. In fact, it looks like a well-thought out plan. Just be a trader for the next few quarters (at the most) and then be a long, if you do not want to be a long now.
Black, perhaps you are forgetting that neither Scarlett nor Huh is a Wall Street guy like Gary Rabin of ACTC; they are both scientists/doctors with a small research-outfit management experience, lacking sensitivity to daily share-price movement. They both are in to get the company to a final destination that, I think, they are doing well. Note that, unlike so many other small biotechs, they have managed a decent cash position and kept the company debt-free and will maintain that condition until Ph III for the MF trial is reached. I can't say they have mismanaged!!
Thanks boy! I stayed away but kept reading what some significant posters like you, ETW, Taz, Black, etc. had posted so far; and, will keep doing so. Especially, I liked some knowledgeable medically significant discussions held herein by certain posters. But, I have decided to indulge to a much lesser extent than I did in the past out of disgust for predomionence of so many others on this board that chew out trash!! Yes, I was very critical of Scarlett and Huh last year but do not think I was fair then!! Well, to opine without having ability or resources to know the complete inside story is always premature! I realized that for myself!!!
I call traders who hop in and out upon assumed signals on minute-by-minute basis, just like monkeys can never sit quiet. I wonder how many of them really make money in the end! Of course, some smart ones do make a bundle occasionally; but, the rest come empty handsin the end or be sore loosers. Yet, they do not give up!!!
Thanks for posting useful and meaningful thoughts. That's what this board should be meant to be used, not for posting rubbish and half-truths.
In my view, Geron has no choice but to get into a partnership or a compatible merger. But, it will be to the best advantage of shareholders if that is done after taking up Ph III trial for MF. Until then, the company has the right size and resources to continue. If the management succeeds in getting accelerated-trial statusfor MF from the FDA (which I am sure it's doing all it can), the time to arrive at that stage will be much shorter than we think. Perhaps, the FDA may advise the management to do so too for the benefit of the medical science and practice. However, the company must build up preliminaries for possible wider applications of Imetelstat, wisely using available resources before accepting any merger deal .
Yes, Taz, I will not deny that; but, I meant institutional investors, not institutional traders like hedge funds. Also, hedge funds using HFT can be is a substantial market manipulator and monkey-action initiator, perhaps making the MM often nervous!! These things will go on until institutional rush crushes those or minimze that influence.
What did the FDA do with this info? Ignore and give license to Sanofi? Sanofi does have its influence at the FDA, isn't it?
verify if Sanofi has hired agents in Wall Street to help keep the Geron share price below $5.00!! This will result in a difficulty for Geron to raise more money. Doing so and postponing licensing of Imtelstat even for as little as a month means Sanofi pockets approx $20M through extended sale of its JAK inhibitor!! Do you think big pharmas are playing such games?
Dr. Silverman IS from NY City!! What do you expect when he is so close to Wall Street and perhaps other vested interests to which rise of Imetelstat is a death nail? Is Cornell not under the influence of its funds contributors?
Thanks, Taz! I had a wrong impression about Sanofi's inhibitor being in the market . It's Novortis and not Sanofi! Thanks for correcting me.
I clicked on the name above and read all of the 180+ posts from Irish, beginning on Nov 15. It's very interesting to read all her posts. She is very consistent and, to me, certainly very credible. Also, to me, she does show her class, consistent with her PhD level education. We all longs must be very thankful to her for sharing the information with us. I, sincerely, wish her and her husband the best for the coming year.
Maine, only a stupid person tends to cut the branch he is standing on!!! I have observed, through majority of your posts that you are impervious to others' thoughts and always critical of others. Have you thought about sincerely judging yourself through the sticks you use for others? It will be a good change for you to be constructive and not critical.
Wouldn't the breakthrough status or fast-track status be determined prior to that based on earlier Geron's ET trials data Mayo's MF data? I believe Geron should be in contact with FDA to gauge this prior to finalizing their multi-center study, to which FDA must be agreeable.
Maine, this is a Yahoo board and not a court of law where you expect a litigator/plaintiff or a defendant required to present a proof of his/her claim. Here, you have to use your common sense to weigh a poster's credibility based on his/her past posts and reasonableness of his/her argument or statement. If you are waiting for Irish's presentation of proof for someone like you on this board, you are way out of line! No poster on this board forces you to believe him/her; you just agree or disagree unless you have facts contrary to the poster's claim. What I am stating is that you MUST come up with facts to refute what Irish states if you want us to believe you.
Excellent thoughts and summary! Your sincere and time-consuming efforts to help and educate others are really praiseworthy. Please keep it up. Happy holidays!
Black, I think 1. This company has many "enemies" who do not want it to succeed, 2. A lot of institutions and individuals have their stake in Incyte/Jakafi some of who (the rogue ones) may be trying to keep Geron down or help stall Imetelstat's progress, and 3. A lot of traders (both institutional ones and retail ones, knowing that Imetelstat is still in Ph I, are just trading in and out everyday to make some bucks! All this will go on until Geron announces a partnership deal or Imetelstat trial reaches Ph III or, at least, news like FDA's breakthrough status is announced. In my sincere opinion now, I think the company is doing all it can to build up shareholder value while bringing up a breakthrough drug for the benefit of those suffering from deadly myeloid cancers. Longs just have to be a bit more patient.
1. Who hires a MM - the company or the exchange?
2. What exactly is his responsibility or duty?
3. How does he operate and how is he supposed to operate?
4. How does he get paid or make money?
5. Who pays him?
Anybody knowing precise answers to these or any of these questions? Please, just be credible!
IWS, I fully concur with what you state despite reservations of some on this board who either lack proper understanding of the science or are overcautious or just plainly shorts. The medicine has been tried on patients who are in the advanced stages and, hence, the results for the larger group most likely would not be worse; perhaps better! And, due to the obvious effectiveness of the drug in targeting myelomic cancer cells and low safety risk, it's quite possible that it will be tried to various other cancers than MF. I have no doubt about it. Scarlett, being a physician himself, has perhaps understood this well and should be trying to get the best possible partnership, if that is what is being planned to do. However, I believe, that it will be naïve to think that the partnership deal is coming soon. In my view, it will be best to wait till near end of 2014, at the earliest, when FDA's decision for the breakthrough status or fast track status would have been out and the company's multi-center trial is well on its way.